FMI Research Offers 10-Year Forecast on Depression And | Page 6

Depression And Seasonal Affective Disorder Therapeutics Market
major brands of SSRI’s which are dominating the on depression and seasonal affective disorder
therapeutics market are Citalopram, Escitalopram, Fluoxetine, and Sertraline.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-3071
Depression and Seasonal Affective Disorder Therapeutics Market: Regional Overview
On the basis of geographical region the depression and seasonal affective disorder therapeutics market is
segmented into seven key regions, viz. North America, Latin America, Western Europe, Eastern Europe,
APEJ, Japan and Middle East & Africa. North America is expected to dominate the global depression and
seasonal affective disorder therapeutics market due to a large number of population suffering from the
seasonal affective disorder. After North America, depression and seasonal affective disorder therapeutics
market is followed by Western Europe owing to advancement in technology and development of new
drugs. In APEJ region India and China is will dominate the depression and seasonal affective disorder
therapeutics market due to rise in geriatric population.
Depression and Seasonal Affective Disorder Therapeutics Market: Key Players
Examples of some of the market participants in depression and seasonal affective disorder
therapeutics market identified across the value chain include Janssen Pharmaceutical Inc., Pfizer Inc.,
Merck & Co., GlaxoSmithKline plc, Sanofi S.A., Eli Lilly and Company, Biogen Idec., Bristol-Myers Sqibb,
Baxter Healthcare Corporation, Novartis AG, Shire plc, AstraZenecaplc.
©2015 Future Market Insights, All Rights Reserved
6